Instagram story viewer> @aaoeye> Post
7 days ago
Last year, the Academy led a coalition of more than 60 physician & patient groups to pressure the federal government’s health watchdog, the HHS Office of Inspector General, to investigate step therapy in Medicare Advantage plans. 

Today, the Academy’s seasoned advocacy team – Michael X. Repka, MD, MBA, medical director for Governmental Affairs, John McAllister, MD, secretary for Federal Affairs, and George Williams, MD, senior secretary for Advocacy – is meeting with the Office of Inspector General (OIG) as it sets out to evaluate whether Medicare Advantage plans are using step therapy tools appropriately.

Step therapy, sometimes called “fail first,” means an insurance plan makes patients try the plan’s preferred drug, and sometimes two or three of them, before it will cover the drug their doctor prescribed. Medicare banned this for doctor-administered drugs (like eye injections) until 2019, when the rules changed to allow it. Since then, its use has grown sharply: 84% of surveyed doctors report seeing more of it, and 94% say it keeps them from prescribing what’s best for their patients.

Today, our advocacy team is telling the OIG what step therapy looks like in practice. They’ll tell the story of the Tennessee patient who was blinded by step therapy. They’ll tell them plans are forcing patients who are already doing well on a drug to switch, requiring drugs that aren’t approved for the condition being treated, and pushing medications favored for financial reasons rather than medical ones. The consequences can be permanent: people with cancer or vision-threatening eye conditions losing critical time.

It’s Important to Know:

✅ The OIG makes recommendations; it’s up to the Centers for Medicare & Medicaid Services (CMS) or Congress to act to implement any policy changes.

✅ The OIG’s objective is to evaluate whether Medicare Advantage plans are using step therapy appropriately, not whether it should exist at all.

How You Can Help:

✅ Share with the Academy stories of patient harm from overutilizing of step therapy or prior authorization. Link in bio

✅ When the Academy puts out the call to contact Congress, heed it.
7
Posted On: October 29th 2026, 03:14 pm
Last year, the Academy led a coalition of more than 60 physician & patient groups to pressure the federal government’s health watchdog, the HHS Office of Inspector General, to investigate step therapy in Medicare Advantage plans.

Today, the Academy’s seasoned advocacy team – Michael X. Repka, MD, MBA, medical director for Governmental Affairs, John McAllister, MD, secretary for Federal Affairs, and George Williams, MD, senior secretary for Advocacy – is meeting with the Office of Inspector General (OIG) as it sets out to evaluate whether Medicare Advantage plans are using step therapy tools appropriately.

Step therapy, sometimes called “fail first,” means an insurance plan makes patients try the plan’s preferred drug, and sometimes two or three of them, before it will cover the drug their doctor prescribed. Medicare banned this for doctor-administered drugs (like eye injections) until 2019, when the rules changed to allow it. Since then, its use has grown sharply: 84% of surveyed doctors report seeing more of it, and 94% say it keeps them from prescribing what’s best for their patients.

Today, our advocacy team is telling the OIG what step therapy looks like in practice. They’ll tell the story of the Tennessee patient who was blinded by step therapy. They’ll tell them plans are forcing patients who are already doing well on a drug to switch, requiring drugs that aren’t approved for the condition being treated, and pushing medications favored for financial reasons rather than medical ones. The consequences can be permanent: people with cancer or vision-threatening eye conditions losing critical time.

It’s Important to Know:

✅ The OIG makes recommendations; it’s up to the Centers for Medicare & Medicaid Services (CMS) or Congress to act to implement any policy changes.

✅ The OIG’s objective is to evaluate whether Medicare Advantage plans are using step therapy appropriately, not whether it should exist at all.

How You Can Help:

✅ Share with the Academy stories of patient harm from overutilizing of step therapy or prior authorization. Link in bio

✅ When the Academy puts out the call to contact Congress, heed it.
Comments (7)
cheetopuffgirl 3 days ago

cheetopuffgirl

this is unacceptable and a literal war crime on our own citizens. 👏 stop 👏 rationing 👏 care 🪞🔪

heathercasparis2020 5 days ago

heathercasparis2020

When will insurers learn that the more durable treatment saves vision and injections? Although US anti-VEGF prices are outrageous. Coming from Switzerland - and I believe we are 2nd to you in overall health cares costs.

jimmypalmamd 7 days ago

jimmypalmamd

The main issue is prevention I this country there is no education and prevention!!! 99% of the USA population doesn’t know what glaucoma is and nobody try to educate them !!! One day your blind and is too late completely preventable!!!! It’s not about price of medication is ignorance!!!

mrinaligupta5 7 days ago

mrinaligupta5

who should we email at the academy about this

ksfarjo 7 days ago

ksfarjo

Perhaps price controls in the medications rather than controlling treatment. That would make big pharma mad and we can't have that

aaoeye 7 days ago

aaoeye

#ophthalmology #advocacy #protectingsightempoweringlives #eyedoctor #patientcare

More posts

back to up